ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2010
[Relationship between the expression of PRDM14 in non-small cell lung cancer and the clinicopathologic characteristics].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14.Nature genetics · 2013Pooled it
- Article
- PRDM14 promotes the migration of human non-small cell lung cancer through extracellular matrix degradation in vitro.Chinese medical journal · 2015Article
- Amplification of chromosome 8 genes in lung cancer.Journal of Cancer · 2015Article
- A mouse model for inducible overexpression of Prdm14 results in rapid-onset and highly penetrant T-cell acute lymphoblastic leukemia (T-ALL).Disease models & mechanisms · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveThe positive regulatory domain proteins (PRDM) are family of transcriptional regulation related to the formation of human tumor factor and play key roles in the cell differentiation and malignant transformation. PRDM14 is a member of the PRDM family. The aim of this study is to detect the expression of PRDM14 in non-small cell lung cancer (NSCLC) tissues, and analyze its relationship with clinicopathologic characteristics of NSCLC.
methodsPRDM14 expression was detected in 70 NSCLC specimens and 7 paracancerous tissues using the immunohistochemistry (SP method). The PRDM14 protein expression was determined in 42 NSCLC specimens and 42 paracancerous tissues by Western blot.
resultsAmong 70 NSCLC specimens, 8 specimens showed weak expression of PRDM14 (11.43%, 8/70), 62 specimens showed moderate to strong staining of PRDM14 (88.57%, 62/70), whereas 7 paracancerous specimens showed weak staining extent. PRDM14 expression level was positively correlated with differentiation (P=0.046) and histological type (P=0.047). The positive cytoplasmic expression of PRDM14 in highly differentiated NSCLC, the low expression of PRDM14 in poorly differentiated NSCLC. The results of Western blot showed that there were significant difference between the two groups (P<0.001); expression of PRDM14 was conspicuous in NSCLC specimens but low in paracancerous tissues. PRDM14 expression level was positively correlated with differentiation (P=0.017). The positive cytoplasmic expression of PRDM14 in highly differentiated NSCLC, the low expression of PRDM14 in poorly differentiated NSCLC.
conclusionsThe high expression of PRDM14 in NSCLC is associated with differentiation and histological type. The PRDM14 may play an important role in the development of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.